Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Mary Jane Meegan

Fellow Emeritus (Pharmacy)

 


Mary J Meegan completed her PhD degree in UCD under the direction of Professor Dervilla Donnelly in the area of natural product chemistry and subsequently carried out postdoctoral research at the University Chemical Laboratory, Cambridge University in the research group of Professor Alan Battersby in the area of porphyrin synthesis and biosynthesis. Following further research periods at University College Dubin and CNRS Gif-sur-Yvette, she was appointed as lecturer in Pharmaceutical Chemistry at the School of Pharmacy and Pharmaceutical Sciences in Trinity College Dublin. She has research experience in the School of Pharmacy and and Pharmaceutical Sciences, Trinity College in the general area of pharmaceutical and medicinal chemistry, with over 100 peer-reviewed scientific papers covering topics such as design and synthesis of anticancer drugs, drug impurity profiling, synthetic methods for library design and in vitro screening. She has extensive experience in scientific and technical management having led an active research group, has acted as Head of the Department of Pharmaceutical Chemistry and as subject area head of Pharmaceutical Chemistry at the School of Pharmacy. Research collaborations have been established within Trinity College with Dr. Niamh O'Boyle (School of Pharmacy and Pharmaceutical Sciences), Dr D Zisterer, Dr D Fayne in the School of Biochemistry and Immunology and also with many European research centres. She is a member of several International Scientific Societies.
  Amphetamines   Anticancer Drug Design   Antiestrogens   Carbapenem antibiotics   Chemistry of drug metabolism   Chemistry of drug receptor interactions   Design and synthesis of drugs   Drug development   Molecular modelling of Estrogen Receptor antagonists   Pharmacologically active heterocycles
 Design, synthesis and evaluation of heterocyclic derivatives of 3,4,5-trimethoxystyrene as microtubule binding agents
 Design and evaluation of novel molecules to target chronic lymphocytic leukaemia (CLL)
 New targets for old drugs: Development of novel -lactams with anticancer activity
 b-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells

Details Date
Guest Editor of Current Topics in Medicinal Chemistry 2005/2006
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
Details Date From Date To
Member of the Royal Society of Chemistry 1977 Present
Member of the American Chemical Society 1997 Present
Member of the Society of the Chemical Industry Chartered Chemist 1990 Present
Andrew J. Byrne, Sandra A. Bright, Darren Fayne, James P. McKeown, Thomas McCabe, Brendan Twamley, Clive Williams and Mary J. Meegan, Synthesis, Antiproliferative and Pro-Apoptotic Effects of Nitrostyrenes and Related Compounds in Burkitt's Lymphoma, Medicinal Chemistry, 14 , (1), 2018, p181 - 199, Notes: [DOI: 10.2174/15734064136661710], Journal Article, PUBLISHED
O'Boyle, NM, Barrett, I, Greene, LM, Carr, M, Fayne, D, Twamley, B, Knox, AJS, Keely, NO, Zisterer, DM, Meegan, MJ, Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity, Journal of Medicinal Chemistry, 61, (2), 2018, p514 - 534, Journal Article, PUBLISHED  TARA - Full Text  DOI  URL
Niamh M. O'Boyle, Daniela M. Zisterer, Mary J. Meegan, Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity, Proceedings of the 3rd Int. Electron. Conf. Med. Chem., 3rd International Electronic Conference on Medicinal Chemistry, November 2017, 3, 2017, Conference Paper, PUBLISHED  DOI  URL
Niamh M. O'Boyle, Daniela M. Zisterer, Mary J. Meegan, Title: Microtubule-Destabilising Actions of Piperlongumine and Analogues, Proceedings of the 3rd Int. Electron. Conf. Med. Chem., 3rd International Electronic Conference on Medicinal Chemistry, November 2017, 3, 2017, Conference Paper, PUBLISHED  DOI  URL
Meegan MJ, Nathwani S, Twamley B, Zisterer DM, O'Boyle NM., Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents., European Journal of Medicinal Chemistry, 125, 2017, p453 - 463, Journal Article, PUBLISHED  TARA - Full Text  DOI
Malebari, AM, Greene, LM, Nathwani, SM, Fayne, D, O'Boyle, NM, Wang, S, Twamley, B, Zisterer, DM, Meegan, MJ, β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells, European Journal of Medicinal Chemistry, 130, 2017, p261-285 , Journal Article, PUBLISHED  DOI  URL
Greene TF, Wang S, Greene LM, Nathwani SM, Pollock JK, Malebari AM, McCabe T, Twamley B, O'Boyle NM, Zisterer DM, Meegan MJ, Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents., Journal of Medicinal Chemistry, 59, (1), 2016, p90 - 113, Journal Article, PUBLISHED  TARA - Full Text  DOI  URL
O'Boyle, N. M. Pollock, J. K. Carr, M. Knox, A. J. Nathwani, S. M. Wang, S. Caboni, L. Zisterer, D. M. Meegan, M. J., beta-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand, Journal of Medicinal Chemistry , 57, (22), 2014, p9370-82 , Journal Article, PUBLISHED  DOI
Pollock, J. K. Verma, N. K. O'Boyle, N. M. Carr, M. Meegan, M. J. Zisterer, D. M., Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway, Biochemical pharmacology, 92, (4), 2014, p544-557 , Journal Article, PUBLISHED  DOI
McNamara, Y. M. Bright, S. A. Byrne, A. J. Cloonan, Suzanne M. McCabe, T. Williams, D. C. Meegan, M. J., Synthesis and antiproliferative action of a novel series of maprotiline analogues, European Journal of Medicinal Chemistry, 2014, Journal Article, PUBLISHED  TARA - Full Text
  

Page 1 of 12
Thomas F. Greene, Thomas McCabe, Mary J. Meegan., The รข-Lactam Ring as a Scaffold for Combretastatin A-4 Analogues, 2006All Ireland Schools of Pharmacy, 28th Research Seminar, Queens University Belfast, April 10-11, 2006, 2006, ppP52-, Conference Paper, PUBLISHED
Cormac A. O'Donohoe, Andrew S. Knox, and Mary J. Meegan, Antiproliferative and physiological stability studies , 2006All Ireland Schools of Pharmacy 28th Research Seminar, Queens University Belfast, April 10-11, 2006, 2006, ppP14-, Conference Paper, PUBLISHED
Jason Horan and Mary J. Meegan, Synthesis and characterisation of 1,2,3,4-tetrahydroisoquinolines:, 2006All Ireland Schools of Pharmacy28th Research Seminar, Queens University Belfast, April 10-11, 2006, 2006, ppP24-, Conference Paper, PUBLISHED
N.O. Keely, M.J. Meegan, Design, synthesis and evaluation of dual acting estrogen receptor conjugates, 2006All Ireland Schools of Pharmacy 28th Research Seminar, Queens University Belfast, April 10-11, 2006, 2006, pp40-, Conference Paper, PUBLISHED
I.M. Barrett, M.J Meegan, D. M.Zisterer., Synthesis and Biochemistry of Some Novel Estrogen Receptor Antagonists , 2006All Ireland Schools of Pharmacy 28th Research Seminar , Queens University Belfast, April 10-11, 2006, 2006, pp12-, Conference Paper, PUBLISHED
Jason Horan and Mary J Meegan, Synthesis of a series of 1,2,3,4-tetrahydroisoquinoline analogues for use as selective estrogen receptor modulators, , Recent Advances in Synthesis and Chemical Biology, Royal College of Surgeons in Ireland, , Dublin, December 15th, 2006, ppP13-, Meeting Abstract, PUBLISHED
Niall O. Keely and Mary J Meegan,, Design and Synthesis and evaluation of dual acting estrogen receptor antagonist conjugates, Recent Advances in Synthesis and Chemical Biology, Royal College of Surgeons in Ireland, Dublin, December 15th, 2006,, 2006, ppP4-, Meeting Abstract, PUBLISHED
Thomas Greene, Tom McCabe and Mary J Meegan, The b-Lactam ring as a scaffold for combretastatin A-4 analogues , , Recent Advances in Synthesis and Chemical Biology, Royal College of Surgeons in Ireland, Dublin, December 15th, 2006,, 2006, ppP31-, Meeting Abstract, PUBLISHED
M.J.Meegan, , Design, synthesis and biochemical studies of novel estrogen receptor antagonists; , 15th Conference of GP2A, University of Bath, , Bath, UK, September 7-8, 2006,, 2006, ppI-4 , Meeting Abstract, PUBLISHED
Thomas Greene, Tom McCabe and Mary J Meegan, , The b- {Lactam ring as a scaffold for combretastatin A-4 analogues , 15th Conference of GP2A, University of Bath, , Bath, UK , September 7-8, 2006,, 2006, ppP16-, Meeting Abstract, PUBLISHED

  

Page 1 of 5
Award Date
Royal Commission 1851 Overseas Postdoctoral Fellowship 1976
Hugh Ryan Gold Medal in Chemistry, University College Dublin 1973
My research interests lie in Pharmaceutical Chemistry in the rational design of new medicines, specifically in the design of highly potent and selective estrogen receptor modulators (SERMs) which may be utilised in the treatment of breast cancer and osteoporosis. Extensive molecular modelling analysis of the specific interactions between drugs such as tamoxifen and raloxifene and models of the protein target (the Estrogen Receptor) has led to the design and synthesis of novel structurally modified estrogen receptor modulators with altered selectivity and affinity for the protein receptor. Ongoing research themes examine the relationship between structure and antiproliferative activity of these products against MCF-7 breast cancer cells, and may lead to a better understanding of the specific structural requirements for estrogen receptor agonist and antagonist activity. This research work is carried out in collaboration with Dr. D. Zisterer and Professor Clive Williams in the School of Biochemistry and Immunology, Trinity College Dublin. Related research interests include the investigation of the mechanism of action of novel cytotoxic heterocycles against breast cancer cell lines (both ER+ and ER-) and CLL(Chronic lymphocytic leukaemia) and the development of virtual high throughput screening computational methodologies for the identification of new anticancer molecular scaffolds. In addition, we have extensive expertise in the area of impurity profiling of amphetamines and related ecstasy type drugs of abuse and also have established current research projects involving the design and evaluation of novel selective serotonin reuptake inhibitors.